Mushrooms changed the world in the 20th century, some say.  Others say, psychedelics are older than humankind. But instead of synthesising molecules and providing it people in a clandestine manner, what if, proper systematic drug discovery and development was done to make psychedelics better?

In this penultimate episode of PsychedeRx, we explore a few more stops before we part ways from this extraordinary project. As we all know, drug trials and molecule development require money and vision and fortitude. So, who exactly is driving the commercialization of psychedelics for responsible clinical use? We’ll hear from Doug Drysdale, CEO of Cybin. as well as Ian McDonald and Gideon Shapiro, CEO and VP of Discovery of Bright Minds Bio respectively. This is not just a hot stock tip, but rather a primer on what the future of the financial side of the psychedelic research and clinical studies. When we said we would cover all aspects of psychedelics in research, we meant it.

This podcast uses the following third-party services for analysis:

Podcorn - https://podcorn.com/privacy